Next Article in Journal
Investigation of the Impact of Cross-Polymerization on the Structural and Frictional Properties of Alkylsilane Monolayers Using Molecular Simulation
Previous Article in Journal
Plasma-Coated Polycaprolactone Nanofibers with Covalently Bonded Platelet-Rich Plasma Enhance Adhesion and Growth of Human Fibroblasts
Previous Article in Special Issue
MMP-9 Downregulation with Lipid Nanoparticles for Inhibiting Corneal Neovascularization by Gene Silencing

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment

Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), University of Granada, 18100 Granada, Spain
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18016 Granada, Spain
Department of Organic Chemistry, Faculty of Sciences. University of Málaga, 29071 Málaga, Spain
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
C.M. and J.M.L.-R. are co-senior authors and contributed equally to this work.
Nanomaterials 2019, 9(4), 638;
Received: 11 March 2019 / Revised: 10 April 2019 / Accepted: 15 April 2019 / Published: 19 April 2019
Many therapeutically active molecules are non-soluble in aqueous systems, chemically and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most promising colloidal carriers for bioactive organic molecules. Their current application in oncology has revolutionized cancer treatment by improving the antitumor activity of several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability, high loading capacity, ease of preparation, low production costs, and large-scale industrial production since they can be prepared from natural sources. Moreover, the association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical trials. This review summarizes the types of LBNPs that have been developed in recent years and the main results when applied in cancer treatment, including essential assays in patients. View Full-Text
Keywords: lipid-based nanoparticles; cancer; drug release; drug resistance; clinical trials lipid-based nanoparticles; cancer; drug release; drug resistance; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

García-Pinel, B.; Porras-Alcalá, C.; Ortega-Rodríguez, A.; Sarabia, F.; Prados, J.; Melguizo, C.; López-Romero, J.M. Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials 2019, 9, 638.

AMA Style

García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, López-Romero JM. Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials. 2019; 9(4):638.

Chicago/Turabian Style

García-Pinel, Beatriz, Cristina Porras-Alcalá, Alicia Ortega-Rodríguez, Francisco Sarabia, Jose Prados, Consolación Melguizo, and Juan M. López-Romero. 2019. "Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment" Nanomaterials 9, no. 4: 638.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop